<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Bone and soft tissue sarcomas, tumors of the skin</journal-id><journal-title-group><journal-title xml:lang="en">Bone and soft tissue sarcomas, tumors of the skin</journal-title><trans-title-group xml:lang="ru"><trans-title>Саркомы костей, мягких тканей и опухоли кожи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4614</issn><issn publication-format="electronic">2782-3687</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">782</article-id><article-id pub-id-type="doi">10.17650/2219-4614-2025-17-4-82-88</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REAL CLINICAL CASES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Surgical treatment of recurrence of solitary fibrotic soft tissue tumor</article-title><trans-title-group xml:lang="ru"><trans-title>Хирургическое лечение рецидива солитарной фиброзной опухоли мягких тканей</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-0400-3331</contrib-id><name-alternatives><name xml:lang="en"><surname>Salkov</surname><given-names>Alexander G.</given-names></name><name xml:lang="ru"><surname>Сальков</surname><given-names>Александр Геннадьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Salkov1994@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8814-8381</contrib-id><name-alternatives><name xml:lang="en"><surname>Petrochenko</surname><given-names>N. S.</given-names></name><name xml:lang="ru"><surname>Петроченко</surname><given-names>Н. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Salkov1994@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5663-8765</contrib-id><name-alternatives><name xml:lang="en"><surname>Namazova</surname><given-names>L. E.</given-names></name><name xml:lang="ru"><surname>Намазова</surname><given-names>Л. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Salkov1994@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-0912-354X</contrib-id><name-alternatives><name xml:lang="en"><surname>Amuchieva</surname><given-names>K. K.</given-names></name><name xml:lang="ru"><surname>Амучиева</surname><given-names>К. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Salkov1994@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3396-4047</contrib-id><name-alternatives><name xml:lang="en"><surname>Beishembaev</surname><given-names>M. I.</given-names></name><name xml:lang="ru"><surname>Бейшембаев</surname><given-names>М. И.</given-names></name></name-alternatives><address><country country="KG">Kyrgyzstan</country></address><email>Salkov1994@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3672-1742</contrib-id><name-alternatives><name xml:lang="en"><surname>Sushentsov</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Сушенцов</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Salkov1994@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Center of Oncology and Hematology, Ministry of Health of Kyrgyz Republic</institution></aff><aff><institution xml:lang="ru">Национальный центр онкологии и гематологии Министерства здравоохранения Кыргызской Республики</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Volga Region Research Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-02-03" publication-format="electronic"><day>03</day><month>02</month><year>2026</year></pub-date><volume>17</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>82</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2026-01-30"><day>30</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-01-30"><day>30</day><month>01</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Salkov A.G., Petrochenko N.S., Namazova L.E., Amuchieva K.K., Beishembaev M.I., Sushentsov E.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Сальков А.Г., Петроченко Н.С., Намазова Л.Э., Амучиева К.К., Бейшембаев М.И., Сушенцов Е.А.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Salkov A.G., Petrochenko N.S., Namazova L.E., Amuchieva K.K., Beishembaev M.I., Sushentsov E.A.</copyright-holder><copyright-holder xml:lang="ru">Сальков А.Г., Петроченко Н.С., Намазова Л.Э., Амучиева К.К., Бейшембаев М.И., Сушенцов Е.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://sarbon.abvpress.ru/jour/article/view/782">https://sarbon.abvpress.ru/jour/article/view/782</self-uri><abstract xml:lang="en"><p>Solitary fibrous tumor (SFT) is a rare neoplasm of mesenchymal origin comprising less than 2 % of all soft tissue tumors. SFT was first described in 1931 by J.H. Kerry who found it in the pleura. Then this tumor was found in various anatomical areas including soft tissues. Considering the absence of standardized methods of treatment for this pathology and radiation and chemotherapy ineffectiveness, surgical treatment is the method of choice. Despite its benign nature, SFT can be aggressive and lead to metastases requiring comprehensive approach to treatment.</p> <p>The article presents clinical features of SFT, the importance of surgical treatment and justification for using multidisciplinary approach, as well as a clinical case of treatment of recurrence involving tumor removal with resection of the femoral vessels and defect reconstruction with vascular implants.</p></abstract><trans-abstract xml:lang="ru"><p>Солитарная фиброзная опухоль (СФО) – редкое новообразование мезенхимального происхождения, на долю которой приходится менее 2 % всех опухолей мягких тканей. Впервые СФО описал в 1931 г. Дж.Х.К. Керри, который обнаружил ее в плевре. Затем эта опухоль была выявлена в различных анатомических областях, включая мягкие ткани. В связи с тем, что стандартизированных методов лечения данной нозологии нет, и из-за неэффективности лучевой и химиотерапии хирургическое лечение является методом выбора. Несмотря на свою доброкачественную природу, СФО может иметь агрессивное течение и приводить к метастазированию, что требует применения комплексного подхода к лечению.</p> <p>В статье представлены клинические особенности СФО, методы ее диагностики, важность хирургического лечения, обосновывается необходимость применения мультидисциплинарного подхода, а также описывается клинический случай хирургического лечения рецидива в объеме удаления опухоли с резекцией бедренных сосудов с замещением дефектов сосудистыми имплантатами.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hemangiopericitoma</kwd><kwd>solitary fibrous tumor</kwd><kwd>vascular prosthesis</kwd><kwd>surgical treatment</kwd><kwd>femoral vessel resction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гемангиоперицитома</kwd><kwd>солитарная фиброзная опухоль</kwd><kwd>протезирование сосудов</kwd><kwd>хирургическое лечение</kwd><kwd>резекция бедренного сосуда</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Правительство РФ</institution></institution-wrap><institution-wrap><institution xml:lang="en">Government of the Russian Federation</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Gengler C., Guillou L. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology 2006;48(1):63–74. DOI: 10.1111/j.1365-2559.2005.02298.x</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Suster S., Nascimento A.G., Miettinen M. et al. Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol 1995;19(11):1257–66. DOI: 10.1097/00000478-199511000-00005</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Rekhi B., Shetty O., Tripathi P. et al. Molecular characterization of a series of solitary fibrous tumors, including immunohistochemical expression of STAT6 and NATB2-STAT6 fusion transcripts, using reverse transcriptase(RT)-polymerase chain reaction(PCR) technique: an Indian experience. Pathol Res Pract 2017;213(11):1404–11. DOI: 10.1016/j.prp.2017.08.011</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Martin-Broto J., Mondaza-Hernandez J.L., Moura D.S., Hindi N. A comprehensive review on solitary fibrous tumor: new insights for new horizons. Cancers (Basel) 2021;13(12):2913. DOI: 10.3390/cancers13122913</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Demicco E.G., Park M.S., Araujo D.M. et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 2012;25(9):1298–306. DOI: 10.1038/modpathol.2012.83</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mlees M.A., Elbarbary A.H., Sallam E.M. Vascular reconstruction using autologous vs synthetic graft for patients with extremity soft-tissue sarcoma involving the major vessels. J Surg Oncol 2020; 121(2):272-278.</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Kozlov N.A., Tsygankova A.V., Abdullaev A.G. Solitary fibrous tumor: features of the clinical course, radiation and laboratory diagnostics, therapy: a review. Sovremennaya onkologiya = Journal of Modern Oncology 2021;23(4):655–9. (In Russ.). DOI: 10.26442/18151434.2021.4.201069</mixed-citation><mixed-citation xml:lang="ru">Козлов Н.А., Цыганкова А.В., Абдуллаев А.Г. Солитарная фиброзная опухоль: особенности клинического течения, лучевой и лабораторной диагностики, терапия. Современная онкология 2021;23(4):655–9. DOI: 10.26442/18151434.2021.4.201069</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Stacchiotti S., Tortoreto M., Bozzi F. et al. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res 2013;19(18):5192–201. DOI: 10.1158/1078-0432.CCR-13-0776</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Stacchiotti S., Negri T., Libertini M. et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol 2012;23(12):3171–9.DOI: 10.1093/annonc/mds143</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Valentin T., Fournier C., Penel N. et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs 2013;31(6):1626–7. Doi: 10.1007/s10637-013-0023-z</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Martin-Broto J., Cruz J., Penel N. et al. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21(3):456–66. DOI: 10.1016/S1470-2045(19)30826-5</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Stacchiotti S., Sommer J. Recurrent and advanced solitary fibrous tumor: multidisciplinary management and future perspectives. Curr Opin Oncol 2015;27(4):316–21. DOI: 10.1016/j.ejca.2018.10.024</mixed-citation></ref></ref-list></back></article>
